Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis

Cancer Research

Volumn 60, Issue 11, 2000, Pages 3065-3071

  Park, Woo H ^a,b   Seol, Jae G ^a   Kim, Eun S ^a   Hyun, Jung M ^a   Jung, Chul W ^c   Lee, Chung C ^b   Kim, Byoung K ^a   Lee, Young Y ^a,d  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN P21;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVITY; GENE CONTROL; GENE INDUCTION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MYELOMA CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING;

APOPTOSIS; ARSENICALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MULTIPLE MYELOMA; OXIDES; PRECIPITIN TESTS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034212785     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. 3 in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89: 3354-3360, 1997.
2. Soignet, S. L., Maslak, P., Wang, Z. G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., Deblasio, A., Gabrilove, J., Scheinberg, D. A., Pandolfi, P. P., and Warrell, R. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 339: 1341-1348, 1998.
3. Shao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W. W., Waxman, S., Pelicci, P. G., Coco, F. L., Avvisati, G., Testa, U., Peschle, C., Passerini, C. G., Nervi, C., and Miller, W. H. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst., 90: 124-133, 1998.
4. 3 exerts dose-dependent dual effects on APL cells. Blood, 89: 3345-3353, 1997.
5. 3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood, 88: 1052-1061, 1996.
6. Zhu, J., Koken, M. H., Quignon, F., Chelbi-Alix, M. K., Degos, L., Wang, Z. Y., Chen, Z., and de The, H. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA, 94: 3978-3983, 1997.
7. Rousselot, P., Labaume, S., Marolleau, J. P., Larghero, J., and Noguera, M. H. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res., 59; 1041-1048, 1999.
8. Li, Y. M., and Broome, J. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res., 59: 776-780, 1999.
9. Zhang, W., Ohnishi, K., Shigeno, K., Fugisawa, S., Naito, K., Nakamura, S., Takeshita, K., Takeshita, A., and Ohno, R. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia, 12: 1383-1391, 1998.
10. Wang, Z. G., Rivi, R., Delva, L., König, A., Scheinberg, D. A., Passerini, C. G., Gabrilove, J. Larrell, R. P., and Pandolfi, P. P. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood, 92: 1497-1504, 1998.
11. Akao, Y., Mizoguchi, H., Kojima, S., Naoe, T., Ohishi, N., and Yagi, K. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br. J. Haematol., 102: 1055-1060, 1998.
12. König, A., Wrazel, L., Warrell, R. P., Rivi, R., Pandolfi, P. P., Jakubowski, A., and Gabrilove, J. L. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood, 90: 562-570, 1997.
13. Dai, J., Weinberg, R. S., Waxman, S., and Jing, Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 93: 268-277, 1999.
14. Sherr, C. J. Cancer cell cycle. Science (Washington DC), 274: 1672-1677, 1996.
15. Morgan, D. O. Principal of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
16. Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J., and Pavletich, N. P. Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex. Nature (Lond.), 376: 313-320, 1995.
17. Dynlacht, B. D. Regulation of transcription by proteins that control the cell cycle. Nature (Lond.), 389: 149-152, 1997.
18. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
19. Peter, M., and Herskowitz, I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell, 79: 181-184, 1994.
20. Elledge, S. J., and Harper, J. W. Cdk inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol., 6: 847-852, 1994.
21. Brugarolas, J., Cliandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 177: 552-557, 1995.
22. Ma, D. C., Sun, Y. H., Chang, K. Z., Ma, X. F., Huang, S. L., Bai, Y. H., Kang, J., Liu, Y. G., and Chu, J. J. Selective induction of apoptosis of NB4 cells from G2 + M phase by sodium arsenite at lower doses. Eur. J. Haematol., 61: 27-35, 1998.
23. Hallek, M., Bergsagel, P. L., and Anderson, K. C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91: 3-21, 1998.
24. Campling, B. G., Pym, J., Galbraith, P. R., and Cole, S. P. C. Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. Leuk. Res., 12: 823-831, 1988.
25. Powell, B. L., Gregory, B. W., Kute, T. E., Morgan, T. M., Lyerly, E. S., and Capizzi, R. L. Bromodeoxyuridine incorporation into DNA of human leukemia cells is not concentration dependent. Cytometry, 11: 438-441, 1990.
26. Vermes, I., Haanen, C., Steffens, N., and Reutelingsperger, C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V. J. Immunol. Methods, 184: 39-51, 1995.
27. Gould, K. L., and Nurse, P. Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis. Nature (Lond.), 342: 39-45, 1989.
28. cdc2 kinase activation in vertebrates. EMBO J., 10: 3331-3341, 1991.
29. Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A., and Yuan, J. Induction of apoptosis in fibroblasts by IL-1 β-converting enzyme, a mammalian homology of the C. elegans cell death gene ced-3. Cell, 75: 653-660, 1993.
30. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T. T., Yu, V. L., and Miller, D. K. Identification and inhibition of the ICE-CED-3 protease necessary for mammalian apoptosis. Nature (Lond.), 376: 37-43, 1995
31. Cohen, G. M. Caspases: the executioners of apoptosis. Biochem. J., 326: 1-16, 1997.
32. Thornberry, N. A., and Lazebnik, Y. Caspases: enemies within. Science (Washington DC), 281: 1312-1316, 1998.
33. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
34. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
35. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671-680, 1990.
36. Martinez, J., Georgoff, I., Martinez, J. A., and Levine, A. J. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev., 5: 151-159, 1991.
37. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 8493-8497, 1995.
38. Stiegler, P., De Luca, A., Bagella, L., and Giordano, A. The COOH-terminal region of pRb/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter. Cancer Res., 58: 5049-5052. 1998.
39. Liu, N., Lucibello, F. C., Engeland, K., and Muller, R. A new model of cell cycle-regulated transcription: repression of the cyclin A promoter by CDF-1 and anti-repression by E2F. Oncogene, 16: 2957-2963, 1998.
40. Spitkovsky, D., Schulze, A., Boye, B., and Jansen-Durr, P. Down-regulation of cyclin A gene expression upon genotoxic stress correlates with reduced binding of free E2F to the promoter. Cell Growth Differ., 8: 699-710, 1997.
41. McGowann, C. H., and Russell, P. Cell cycle regulation of human WEE1. EMBO J., 14: 2166-2175, 1995.
42. 2. Genetics, 87: 5139-5143, 1990.
43. Maller, J. L. Mitotic control. Curr. Opin. Cell Biol., 3: 269-275, 1991.
44. Dunphy, W. G., and Kumagai, A. The cdc25 protein contains an intrinsic phosphatase activity. Cell, 67: 189-196, 1991.
45. 2 cell cycle arrest in human keratinocytes by inhibitory phosphorylation of the cdc2 cell cycle kinase. Oncogene, 11: 2151-2156, 1995.
46. Ishitsuka, K., Hanada, S., Suzuki, S., Utsunomiya, A., Chyuman, Y., Takeuchi, S., Takeshita, T., Shimotakahara, S., Uozumi, K., Makino, T., and Arima, T. Arsenic acid inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br. J. Haematol., 101: 721-728, 1998.
47. Yang, E., and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88: 386-401, 1996.
48. Lichtenstein, A., Tu, Y., Fady, C. Vescio, R., and Berenson, J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol., 162: 248-256, 1995.
49. Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., and Epstein, J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 84: 3063-3070, 1994.
50. Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D. W., and Anderson, K. C. Interleukin-6 inhibits Fas-induced apoptosis and SAP kinase activation in multiple myeloma cells. Blood, 89: 227-234, 1997.